Novel serum tumor marker, RCASl, in pancreatic diseases

查看全文 作　　者：Koji [1]Yamaguchi;Munechika [2]Enjoji;Manabu [3]Nakashima;Makoto [2]Nakamuta;Takashi [4]Watanabe;Masao [1]Tanaka

机构地区：[1]Department of Surgery and Oncology Graduate School of Medicine, Kyushu University, Japan;[2]Medicine Bioregulatory Sciences Graduate School of Medical Sciences, Kyushu University, Japan;[3]Department of Molecular Immunology Medical Institute of Bioregulation, Faculty of Medicine,Kyushu University,Japan;[4]Department of Molecular Immunology Medical Institute of Bioregulation, Faculty of Medicine, Kyushu University, Japan

出　　处：《World Journal of Gastroenterology》索引2005年第11卷第33期,共4页

摘　　要：AIM: As tumor markers for pancreatic carcinoma,carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 have been used, but the sensitivity and specificity are not enough for the diagnosis of pancreatic carcinoma.METHODS: A novel serum tumor marker, RCAS1, was compared with two conventional serum tumor markers,CEA (highly specific for pancreatic cancer) and CA 19-9 (highly sensitive for pancreatic cancer), in 48 patients with pancreatic exocrine tumors.RESULTS: When the diagnosis of benign or malignant conditions was examined by one tumor marker, the sensitivity of RCAS1 alone (55%) was higher than that of CEA alone (27%) and the specificity of RCAS1 alone (92%) was greater than that of CA19-9 alone (78%). When examined by a combination of two markers, the sensitivity of a combination of RCAS1 and CA19-9 (95%) was superior to those of CA19-9 alone (78%), RCAS1 alone (55%, P = 0.002),CEA alone (27%) (P<0.001), RCAS1 and CEA (59%) and CA19-9 and CEA (82%).CONCLUSION: These results suggest that the combination of RCASL and CA19-9 is highly sensitive for pancreatic carcinoma. 关键词：血浆肿瘤标记物 RCAS1 胰腺癌病理机制抗原

相关文献

参考文献（17）
引证文献（13）
耦合文献（0）

参考文献(17)

引证文献(13)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Novel serum tumor marker, RCASl, in pancreatic diseases

参考文献(17)

引证文献(13)

用户提示